The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purposes of this study are to learn whether treatment with an androgen type hormone will improve the visual-spatial problems associated with Turner syndrome, and to evaluate the effect growth hormone, with and without androgen, has on growth.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Thomas Jefferson University
• Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
• Treatments: Androgens; Ascorbic Acid; Estrogens; Estrogens, Conjugated (USP); Hormones; Methyltestosterone

Criteria

• Karyotype diagnosis compatible with Turner syndrome, but no presence of any Y material in the peripheral karyotype unless a gonadectomy has been performed;

• Chronological age between 10.0 and 14.9 years;

• Bone age less than or equal to 12 years; and

• No treatment with estrogen, androgen, growth hormone, or any other growth-promoting agents exceeding 12 months, and no treatment with any of these agents in the previous 3 months.